Ception is reporting mixed results from a Phase IIb/III trial of Cinquil (reslizumab), a drug for a type of inflammation of the esophagus called pediatric eosinophilic esophagitis. Patients taking the ...

A fresh batch of positive, mid-stage asthma data has persuaded Cephalon to exercise its option to buy Ception Therapeutics for a minimum of $250 million. That payout comes on top of the $100 million ...

If Phase III data on eosinophilic esophagitis drug is positive, Cephalon will pay $250 million to take over Ception. Cephalon will pay $100 million up front for an option to purchase Ception ...

Malvern, Pa.-based Ception Therapeutics, a biotech developing drugs to treat inflammatory disease, raised an additional $14.7 million in its third funding round, bringing the total round to $77 ...

Ception's lead product is reslizumab. Reslizumab is a humanized monoclonal antibody (mAb) against interleukin-5 (IL-5) currently in a Phase IIb/III clinical trial for the treatment of pediatric ...

After reporting positive Phase II clinical results for its asthma treatment reslizumab, Ception Therapeutics is being acquired by Cephalon for $250 million. Cephalon paid $100 million for an option to ...